Arcus Biosciences, Inc. (RCUS)
| Market Cap | 2.40B |
| Revenue (ttm) | 77.78M |
| Net Income (ttm) | -87.60M |
| Shares Out | 62.60M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $36.98 |
| Previous Close | $38.83 |
| Change ($) | -1.85 |
| Change (%) | -4.76% |
| Day's Open | 39.03 |
| Day's Range | 34.83 - 40.01 |
| Day's Volume | 939,455 |
| 52-Week Range | 8.78 - 40.01 |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented prelimina...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that prel...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andr...
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269....
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that mana...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced a collabo...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jenn...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Arcus Biosciences, Inc.: An Oncology Stock With Newfound Prominence
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob ...
Is (RCUS) Outperforming Other Medical Stocks This Year?
Is (RCUS) Outperforming Other Medical Stocks This Year?
Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The development-stage biopharma is bouncing back from a recent stock dip.
Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.
The deal gives Gilead access to a new pipeline of potential cancer immunotherapies.
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020.
Is (RCUS) Outperforming Other Medical Stocks This Year?
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Shares of Arcus Biosciences Inc. RCUS, +88.44% soared 87% in trading on Thursday after people familiar with the matter told Bloomberg News that Gilead Sciences Inc.
The two companies are apparently discussing either an equity purchase or some other form of cooperation.
Arcus Biosciences stock rocketed to a record high Thursday on reports suggesting Gilead Sciences could be interested in acquiring a stake in the Alphabet-backed biotech company.
Does Arcus Biosciences, Inc. (RCUS) have what it takes to be a top stock pick for momentum investors?
Arcus Biosciences stock is on fire in response to a possible partnership deal with Gilead Sciences.
Arcus Biosciences (RCUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Arcus Biosciences Anti-TIGIT Candidate Puts Company In The Shop Window
Top Ranked Momentum Stocks to Buy for March 13th
Efforts to contain COVID-19 are putting the entire biopharmaceutical industry in a jam.
The coronavirus induced sell-off has created a number of attractive buying opportunities.
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Can these high-flying biotech stocks keep up their sizzling momentum?
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -8.51% and 30.60%, respectively, for the quarter ended September 2019.
CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 21,738 shares of RCUS on 06/06/2019 at an average price of $7.93 a share.
CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 41,540 shares of RCUS on 06/04/2019 at an average price of $7.91 a share.
Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results
ARCUS gene editing platform may be more specific and have less off-target side effects than CRISPR/Cas9.
As of late, it has definitely been a great time to be an investor in Arcus Biosciences, Inc. (RCUS).
About RCUS
Arcus Biosciences, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in... [Read more...]
| Industry Biotechnology | IPO Date Mar 15, 2018 |
| CEO Dr. Terry J. Rosen Ph.D. | Employees 139 |
| Stock Exchange NYSE | Ticker Symbol RCUS |
Financial Performance
In 2019, RCUS's revenue was $15.00 million, an increase of 79.58% compared to the previous year's $8.35 million. Losses were -$84.71 million, 70.8% more than in 2018.
Analyst Forecasts
According to 11 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is 42.00, which is an increase of 13.57% from the latest price.